<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4325">
  <stage>Registered</stage>
  <submitdate>12/02/2014</submitdate>
  <approvaldate>12/02/2014</approvaldate>
  <nctid>NCT02063659</nctid>
  <trial_identification>
    <studytitle>Telotristat Etiprate for Carcinoid Syndrome Therapy</studytitle>
    <scientifictitle>A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome</scientifictitle>
    <utrn />
    <trialacronym>TELECAST</trialacronym>
    <secondaryid>LX1606.303</secondaryid>
    <secondaryid>LX1606.1-303-CS</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Carcinoid Syndrome</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Research that is not of generic health relevance and not applicable to specific health categories listed above</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Neuroendocrine tumour (NET)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Telotristat etiprate tablets (250 mg)
Treatment: drugs - Placebo

Experimental: 250 mg telotristat etiprate - One telotristat etiprate (250 mg) tablet and one placebo tablet administered three times daily

Experimental: 500 mg telotristat etiprate - Two telotristat etiprate (250 mg) tablets administered three times daily

Placebo Comparator: Placebo - Two placebo tablets administered three times daily


Treatment: drugs: Telotristat etiprate tablets (250 mg)
Telotristat etiprate (250 mg) in tablet form.

Treatment: drugs: Placebo
Matching placebo in tablet form

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of Treatment-emergent Adverse Events</outcome>
      <timepoint>12 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percent Change From Baseline in 24-hour Urinary 5-hydroxyindoleacetic Acid (5-HIAA)</outcome>
      <timepoint>Week 12</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in the Number of Daily Bowel Movements</outcome>
      <timepoint>Baseline and 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Stool Consistency - Patients rate stool consistency using the Bristol Stool Scale. The Bristol Stool Chart shows seven categories of stool. Type 1-2 indicate constipation, Type 3-4 are ideal stools as they are easier to pass, and Type 5-7 may indicate diarrhea and urgency.</outcome>
      <timepoint>Baseline and 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in the Number of Cutaneous Flushing Episodes</outcome>
      <timepoint>Baseline and 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Abdominal Pain - Patients record the level of any abdominal pain they feel in the daily diary using an 11- point numeric rating system (NRS) based on the following: "Rate your worst abdominal (belly or tummy) pain in the past 24 hours, with "0" being "no pain" and "10" being "worst pain ever experienced"."</outcome>
      <timepoint>Baseline and 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in the Frequency of Rescue Short-acting, Somatostatin Analog Used to Treat Carcinoid Syndrome Symptoms</outcome>
      <timepoint>Baseline and 12 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patients = 18 years of age

          -  All patients of reproductive potential must agree to use an adequate method of
             contraception during the study and for 12 weeks after the Follow-up visit.

          -  Histopathologically-confirmed, well-differentiated metastatic neuroendocrine tumor

          -  Documented history of carcinoid syndrome

          -  Patient is able and willing to provide written informed consent prior to participation</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Presence of diarrhea attributed to any condition other than carcinoid syndrome.

          -  Presence of 12 or more watery bowel movements per day

          -  Positive stool examination for enteric pathogens, pathogenic ova or parasites, of
             Clostridium difficile at Screening

          -  Karnofsky Performance Status = 60%

          -  Presence of any clinically significant laboratory, medical history, or physical
             examination findings deemed unacceptable by the Investigator

          -  A history of short bowel syndrome

          -  History of constipation within 2 years of Screening

          -  Life expectancy &lt; 12 months from Screening</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>11/03/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>76</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>29/03/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC</recruitmentstate>
    <hospital>Lexicon Investigational Site - Kogara</hospital>
    <hospital>Lexicon Investigational Site - St. Leonards</hospital>
    <hospital>Lexicon Investigational Site - Herston</hospital>
    <hospital>Lexicon Investigational Site - East Melbourne</hospital>
    <postcode>2217 - Kogara</postcode>
    <postcode>2065 - St. Leonards</postcode>
    <postcode>4029 - Herston</postcode>
    <postcode>3002 - East Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Edegem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Yvoir</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Strasbourg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Villejuif</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Berka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heidelberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Lubeck</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mainz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Marburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Neuss</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Jerusalem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Noord-Holland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Noord Brahant</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Uppsala</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Basingstoke Hampshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Coventry</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Newcastle upon Tyne</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Lexicon Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the study is to evaluate the effect of telotristat etiprate versus placebo on
      the incidence of treatment-emergent adverse events and on 5-hydroxyindoleacetic acid (5-HIAA)
      levels.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02063659</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Pablo Lapuerta, MD</name>
      <address>Lexicon Pharmaceuticals, Inc.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>